H. Stewart Parker

H. Stewart Parker

H. Stewart Parker

Overview
Career Highlights

Receptech Corp.
Infectious Disease Research Institute
Immunex Corp.

RelSci Relationships

1511

Number of Boards

21

Birthday

1956

Age

64

Contact Data
Trying to get in touch with H. Stewart Parker? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals H. Stewart Parker likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former Executive Chairman at Infectious Disease Research Institute

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Achieve Life Sciences, Inc.

Relationship likelihood: Strong

Professor at University of Washington

Relationship likelihood: Strong

Director, President & Chief Executive Officer at Sangamo Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Impel NeuroPharma, Inc.

Relationship likelihood: Strong

Chief Financial Officer & Director at Infectious Disease Research Institute

Relationship likelihood: Strong

President & Chief Scientific Officer at Achieve Life Sciences, Inc.

Relationship likelihood: Strong

Managing Director at ARCH Venture Partners

Relationship likelihood: Strong

Former Vice Chairman at Infectious Disease Research Institute

Relationship likelihood: Strong

Chief Executive Officer at BioScience Managers Pty Ltd

Relationship likelihood: Strong

Paths to H. Stewart Parker
Potential Connections via
Relationship Science
You
H. Stewart Parker
Education
BA in Slavic Language & Literature
Class of 1981

Founded in 1861 by a private gift of 10 acres in what is now the heart of downtown Seattle, the UW is one of the oldest public universities on the West Coast. We’re deeply committed to upholding the responsibility that comes with that legacy. And being public has always meant being accessible. Anyone can enjoy and be enriched by all the UW has to offer, including world-class libraries, art, music, drama, sports and the highest quality medical care in Washington state. Being public also means being engaged with our communities, and through knowledge and discovery we are elevating the quality of lives of others.

MBA in Finance & International Business

University of Washington Michael G. Foster School of Business is the business school at the University of Washington, Seattle. It was founded in 1917 and is the second oldest institution of management education on the West Coast (behind the Haas School of Business). The school has nearly 46,000 alumni, and is accredited by the Association to Advance Collegiate Schools of Business and the European Quality Improvement System (EQUIS). The School is one of four U.S. business schools to earn the EQUIS. The school offers bachelor's, master's, and doctoral degrees. Enrollment each year is about 2,500 students in its undergraduate and graduate programs and over 1,000 working professionals in its executive education seminars and lifelong learning programs. Foster School of Business MBA program is ranked as 23rd in the nation by US News and 37th by Businessweek. An objective ranking of Faculty Scholarly Productivity Index by Academic Analytics ranks University of Washington #1 in research productivity in Business Administration and #8 in marketing.The Foster School's Custom Executive Education Programs are ranked fourth of their kind by The Economist. UW Center for Innovation and Entrepreneurship is ranked fifth best in the country by Entrepreneur magazine.

Career History
President & Chief Executive Officer
1991 - 1993

Receptech Corp., a subsidiary of Amgen, Inc., is an American company located in Seattle, WA, that sells Immunex products. The firm was acquired by Immunex Corp., a subsidiary of Amgen, Inc. since July 2002, on 16 Dec 92 for $59.40 million.

Director
Tenure Unconfirmed

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Sangamo was founded in 1995, went public in 2000, and trades on the Nasdaq Global Market (SGMO). We are located in Richmond, California, in the Bay Area, the birthplace of biotechnology. We are intimately involved in our community through partnerships with academic institutions, relationships with non-profit organizations and ties to advocacy organizations aligned with improving the quality of life for patients with unmet medical needs within our strategic vision.

Principal
Tenure Unconfirmed
Boards & Committees
Director
2014 - Current

Nexgenia, Inc. develops molecule-specific selection reagents. Its technology include polymer-protein conjugates and magnetic nanoparticles. The company was founded by James Lai and Thomas Schulte in February 2011 and is headquartered in Seattle, WA.

Director
2005 - 2009

The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market.

Director
Prior

Regence BlueShield provides health insurance services. It also provides group and individual medical, dental and vision health insurance plans. The firm’s insurance products include HMO, supplemental Medicare and traditional indemnity. The company is headquartered in Seattle, WA.

Senior Advisor
2011 - Prior

Infectious Disease Research Institute operates as a innovative science to research and development company. It offers pipeline, adjuvants, vaccines, diagnostics and drugs products. The firm also provides manufacturing, analytical methods, stability studies, process and contact services. The company was founded by Steven G. Reed in 1993 and is headquartered in Seattle, WA.

Director
1996 - 2008

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Member, Board of Directors
Prior

COPPER CANYON PRESS PUBLISHES EXTRAORDINARY POETRY FROM AROUND THE WORLD TO ENGAGE THE IMAGINATIONS AND INTELLECTS OF READERS

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$10K - $100K
2017

The University of Washington Foundation is a non-profit, public 501(c)(3) organization that advances the mission of the University of Washington by seeking and securing private support for its programs in service to students and society. The Foundation is a conduit for giving to University of Washington students, faculty, programs and/or facilities; gifts are applied to the UW fund or allocated as designated by the donors.

$5,000 - $10K
2017

Global Partnerships invests in partnerships with local organizations that use market-based solutions for people living in poverty. The firm invests in the areas such as health services, rural livelihoods, green technology and microentrepreneurship. The company was founded by Paula Clapp and Bill Clapp in 1994 and is headquartered in Seattle, WA.

$2,500 - $4,999
2016

Global Partnerships invests in partnerships with local organizations that use market-based solutions for people living in poverty. The firm invests in the areas such as health services, rural livelihoods, green technology and microentrepreneurship. The company was founded by Paula Clapp and Bill Clapp in 1994 and is headquartered in Seattle, WA.

Political Donations
$250
2013

Former Staffer at Washington State Senate

$250
2013

Representative from Washington's 6th Congressional District

$250
2012

Representative from Washington's 6th Congressional District

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by H. Stewart Parker. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of H. Stewart Parker's profile does not indicate a business or promotional relationship of any kind between RelSci and H. Stewart Parker.